Abstract
Metastasis is the cause of most cancer mortality. Circulating tumour cells (CTC) are cells that are released from a primary tumour into the bloodstream and that are considered to act as the main promoters of metastasis. These cells are therefore targets for the understanding of tumour biology and an improvement of clinical management of the disease. Early detection of CTC and analysis of their cell surface markers provide critical information for the diagnosis of cancer and its target therapy. CTC are shed into the bloodstream as tumours grow, and are believed to initiate the spread of cancer. The identification and analysis of CTC is thus an important objective for the development of noninvasive cancer diagnosis. Methods of capture and detection of CTC have been complicated and costly, and the captured cells could not be cultured and expanded directly. Because CTC are rare, existing as only a few per one billion blood cells, a highly efficient method is required to capture and to culture CTC for further assay. Chipbased and traditional methods have emerged to isolate, to detect and to characterize CTC. As CTC are a rare event, their investigation requires multidisciplinary considerations of both biological and physical properties. Chip-based biosensor platforms are being introduced into the technology for the quantification of CTC with promising results. This review describes recent progress in the identification of CTC; the approach developed has a simple workflow and scalable multiplexing, which makes it ideal for further investigation of CTC biomarkers.
Keywords: Biomarkers, Cancer, Chip-based biosensor, Circulating tumour cells (CTC), Metastasis, Non-invasive.
Current Topics in Medicinal Chemistry
Title:Detection of Cancer Cells on a Chip
Volume: 15 Issue: 15
Author(s): Hsu-Chao Hao and Da-Jeng Yao
Affiliation:
Keywords: Biomarkers, Cancer, Chip-based biosensor, Circulating tumour cells (CTC), Metastasis, Non-invasive.
Abstract: Metastasis is the cause of most cancer mortality. Circulating tumour cells (CTC) are cells that are released from a primary tumour into the bloodstream and that are considered to act as the main promoters of metastasis. These cells are therefore targets for the understanding of tumour biology and an improvement of clinical management of the disease. Early detection of CTC and analysis of their cell surface markers provide critical information for the diagnosis of cancer and its target therapy. CTC are shed into the bloodstream as tumours grow, and are believed to initiate the spread of cancer. The identification and analysis of CTC is thus an important objective for the development of noninvasive cancer diagnosis. Methods of capture and detection of CTC have been complicated and costly, and the captured cells could not be cultured and expanded directly. Because CTC are rare, existing as only a few per one billion blood cells, a highly efficient method is required to capture and to culture CTC for further assay. Chipbased and traditional methods have emerged to isolate, to detect and to characterize CTC. As CTC are a rare event, their investigation requires multidisciplinary considerations of both biological and physical properties. Chip-based biosensor platforms are being introduced into the technology for the quantification of CTC with promising results. This review describes recent progress in the identification of CTC; the approach developed has a simple workflow and scalable multiplexing, which makes it ideal for further investigation of CTC biomarkers.
Export Options
About this article
Cite this article as:
Hao Hsu-Chao and Yao Da-Jeng, Detection of Cancer Cells on a Chip, Current Topics in Medicinal Chemistry 2015; 15 (15) . https://dx.doi.org/10.2174/1568026615666150414150950
DOI https://dx.doi.org/10.2174/1568026615666150414150950 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Role of Genomics-Based Strategies in Overcoming Chemotherapeutic Resistance
Current Pharmaceutical Biotechnology Sustained Delivery of Tamoxifen from a Nanofluidic Delivery Platform
Drug Delivery Letters Chemotherapeutic Effects of Acridine Derivatives
Medicinal Chemistry Reviews - Online (Discontinued) Structure-Function Relationship of Vpr: Biological Implications
Current HIV Research Atopic Dermatitis and Cytokines: Recent Patents in Immunoregulatory and Therapeutic Implications of Cytokines in Atopic Dermatitis - Part I: Cytokines in Atopic Dermatitis
Recent Patents on Inflammation & Allergy Drug Discovery Editorial: (Thematic Issue Cancer Immunotherapy: Does an Increasing Arsenal of Tools Point to More Fruitful Avenues for Research?)
Anti-Cancer Agents in Medicinal Chemistry Metabolomics for Personalized Nutrition Research and Clinical Applications
Current Pharmacogenomics and Personalized Medicine Transcriptional Regulation of mPGES1 in Cancer: An Alternative Approach to Drug Discovery?
Current Drug Targets Update on the Development of microRNA and siRNA Molecules as Regulators of Cell Physiology
Recent Patents on DNA & Gene Sequences Targeting Tumor Angiogenesis in Gastrointestinal Malignancies
Current Angiogenesis (Discontinued) Probenecid: An Emerging Tool for Neuroprotection
CNS & Neurological Disorders - Drug Targets Cellular and Molecular Effects of Beta Radiation from I-131 on Human Tumor Cells a Comparison with Gamma Radiation
Current Radiopharmaceuticals Implications of Photophysical and Physicochemical Factors on Successful Application of Photodynamic Therapy
Current Pharmaceutical Design Cytotoxicity and Toxicity to Animals and Humans of Ribosome-Inactivating Proteins
Mini-Reviews in Medicinal Chemistry Purinergic Receptors and Pain
Current Pharmaceutical Design Synthesis and Antiproliferative Activity of New Polyoxo 2-Benzyl-2,3- dihydrobenzofurans and Their Related Compounds
Letters in Drug Design & Discovery In the Crosshairs: NF-κB Targets the JNK Signaling Cascade
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Novobiocin and Additional Inhibitors of the Hsp90 C-Terminal Nucleotide- binding Pocket
Current Medicinal Chemistry Cardio-Hepatic Metabolic Derangements and Valproic Acid
Current Clinical Pharmacology Muscarinic Activation Enhances the Anti-proliferative Effect of Paclitaxel in Murine Breast Tumor Cells
Anti-Cancer Agents in Medicinal Chemistry